




IFW

Patent Docket P0957R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Robert B. Fick et al. Serial No.: 10/826,797 Filed: April 16, 2004 For: Methods for Treatment of Allergic Asthma	Group Art Unit: 1614 Examiner: not yet known Confirmation No: 1468 CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 28, 2004  Christine Ricks
--	---

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

0 **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes

prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

(If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.)

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because **a)**(X) they were previously cited by or submitted to the Office in a prior application Serial No. 08/686,902, filed July 26, 1996 and relied upon in this application for an earlier filing date under 35 USC §120 and/ or because **b)**(X) this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under

35 USC §371 after June 30, 2003 (**1276 OG 55**). Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-0" (nucleotide) and "BLAST Results B-1 - B-0" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) (Required)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC

By: 

Craig G. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489

Date: July 28, 2004

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0957R1C1Serial No.
10/826,797

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Fick, Jr. et al.Filing Date
16 Apr 2004

Group

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,714,759	22.12.87	Whitaker, Jr.			
	* 2	4,816,567	28.03.89	Cabilly et al.			
	* 3	4,861,579	29.08.89	Meyer et al.			
	* 4	4,940,782	10.07.90	Rup et al.			
	* 5	4,946,788	07.08.90	Delespesse			
	* 6	4,962,035	09.10.90	Leder et al.			
	* 7	5,091,313	25.02.92	Chang, T.			
	* 8	5,231,026	27.07.93	Chang, T.			
	* 9	5,252,467	12.10.93	Chang, T.			
	* 10	5,254,671	19.10.93	Chang, T.			
	* 11	5,260,416	09.11.93	Chang, T.			
	* 12	5,274,075	28.12.93	Chang, T.			
	* 13	5,292,867	08.03.94	Chang, T.			
	* 14	5,342,924	30.08.94	Chang, T.			
	* 15	5,362,643	08.11.94	Chang, T.			
	* 16	5,420,251	30.05.95	Chang et al.			
	* 17	5,422,258	06.06.95	Chang, T.			
	* 18	5,428,133	11.12.91	Chang, T.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	* 19	171,496	19.02.86	EPO				
	* 20	173,494	05.03.86	EPO				
	* 21	184,187	11.06.86	EPO				
	* 22	255,249	03.02.88	EPO				
	* 23	263,655	13.04.88	EPO				
	* 24	317,295	24.05.89	EPO				
	* 25	589,840	30.03.94	EPO				
	* 26	617,127	28.09.94	EPO				
	* 27	648,499	19.04.95	EPO				
	* 28	58-156285	17.09.83	JAPAN				
	* 29	WO 86/01533	13.03.86	PCT				
	* 30	WO 89/04834	01.06.89	PCT				
	* 31	WO 89/06138	13.07.89	PCT				
	* 32	WO 89/06692	27.07.89	PCT				
	* 33	WO 91/11456	08.08.91	PCT				

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797			
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.				
				Filing Date 16 Apr 2004	Group			
FOREIGN PATENT DOCUMENTS								
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	* 34	WO 92/22653	23.12.92	PCT				
	* 35	WO 93/04173	04.03.93	PCT				
	* 36	WO 93/19197	30.09.93	PCT				
	* 37	WO 95/15977	15.06.95	PCT				
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)								
	38	Alexander et al., "Trial of Cyclosporin in Corticosteroid-dependent Chronic Severe Asthma" <u>Lancet</u> 339:324-328 (Feb 8, 1992)						
	39	Aquino et al., "Chronic Pulmonary Disorders in Sickle Cell Disease: Findings at Thin-Section CT" <u>Radiology</u> pps. 807-811						
	40	Bam et al., "Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique" <u>Pharm. Res.</u> 12:2-11 (1995)						
	* 41	Baniyash et al., "Anti-IgE monoclonal antibodies directed at the Fc ϵ receptor binding site" <u>Molecular Immunology</u> 25(8):705-711 (1988)						
	* 42	Baniyash et al., "Inhibition of IgE Binding to Mast Cells and Basophils by Monoclonal Antibodies to Murine IgE" <u>European Journal of Immunology</u> 14:799-807 (1984)						
	43	Baur et al., "Levels of Complement Factors in Human Serum during Immediate and Late Asthmatic Reactions and during Acute Hypersensitivity Pneumonitis" <u>Allergy, Munksgaard, Copenhagen</u> 35:383-390 (1980)						
	44	Behrens et al., "Modulation of the Late Asthmatic Response by Antigen-Specific Immunoglobulin G in an Animal Model" <u>Am. Rev. Respir. Dis.</u> 130:1134-1139 (1984)						
	45	Bentley et al., "Comparison of the Immunopathology of Extrinsic, intrinsic and occupational asthma" <u>Invest. Allergol. Clin. Immunol.</u> 4(5):222-232 (Sep 1994)						
	46	Bentley et al., "Human Late Asthmatic Reactions" <u>Clinical and Experimental Allergy</u> (Supplement 1) 27:71-86 (1997)						
	47	Bentley et al., "Increases in Activated T Lymphocytes, Eosinophils, and Cytokine mRNA Expression for Interleukin-5 and Granulocyte/Macrophage Colony-stimulating Factor in Bronchial Biopsies after Allergen Inhalation Challenge in Atopic Asthmatics" <u>Am. J. Respir. Cell Mol. Biol.</u> 8:35-42 (1993)						
	* 48	Berglund et al., "Spirometric studies in normal subjects" <u>Acta. Med. Scand.</u> 173:185-192 (1963)						
	* 49	Blank et al., "Characterization of Truncated α Chain Products from Human, Rat, and Mouse High Affinity Receptor for Immunoglobulin E" <u>Journal of Biological Chemistry</u> 266(4):2639-2646 (February 5, 1991)						
	50	Booij-Noord et al., "Late Bronchial Obstructive Reaction to Experimental Inhalation of House Dust Extract" <u>Clinical Allergy</u> 2:43-61 (1972)						
	51	Boulet et al., "Inhibitory Effects of an Anti-IgE Antibody E25 on Allergen-induced Early Asthmatic Response" <u>Am J Respir Crit Care Med</u> 155:1835-1840 (1997)						
	52	Boulet et al., "Prediction of Late Asthmatic Responses to Inhaled Allergen" <u>Clinical Allergy</u> 14:379-385 (1984)						
	* 53	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)						
Examiner				Date Considered				
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	* 54	Bozelka et al., "Effects of Anti-ε on Total and Specific IgE Levels in Adult Mice" <u>Int. Archs. Allergy Appl. Immun.</u> 78:51-56 (1985)			
	* 55	Bozelka et al., "IgE isotype suppression in anti-ε-treated mice" <u>Immunology</u> 46:527-532 (1982)			
	* 56	Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (April 1991)			
	* 57	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <u>Journal of Cell Biology</u> 111:2129-2138 (1990)			
	* 58	Burrows et al., "Association of asthma with serum IgE levels and skin-test reactivity to allergens" <u>New England J. of Medicine</u> 320(5):271-277 (Feb. 2, 1989)			
	* 59	Burt et al., "Analysis of the interaction between rat immunoglobulin E and rat mast cells using anti-peptide antibodies" <u>Molecular Immunology</u> 24(4):379-389 (1987)			
	* 60	Burt et al., "Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides" <u>European Journal of Immunology</u> 17:437-440 (1987)			
	61	Campbell et al., "Interaction Between Isoprenaline and Aminophylline in Asthma" <u>Thorax</u> 32:424-428 (1977)			
	62	Carmichael et al., "Corticosteroid Resistance in Chronic Asthma" <u>British Medical Journal</u> 282:1419-1422 (May 2, 1981)			
	* 63	Chang et al., "Monoclonal Antibodies Specific for Human IgE-producing B Cells: A Potential Therapeutic for IgE-mediated Allergic Diseases" <u>Bio/Technology</u> 8:122-126 (February 1990)			
	64	Claman et al., "Analysis of Induced Sputum to Examine the Effects of Prednisone on Airway Inflammation in Asthmatic Subjects" <u>J. Allergy Clin. Immunol.</u> pps. 861-869 (Nov 1994)			
	* 65	Co et al., "Humanized antibodies for antiviral therapy" <u>Proc. Natl. Acad. Sci. USA</u> 88:2869-2873 (April 1991)			
	* 66	Cockcroft et al., "Allergen-induced increase in non-allergic bronchial reactivity" <u>Clinical Allergy</u> 7:503-513 (1977)			
	67	Cockcroft et al., "Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine" <u>J. Allergy Clin. Immunol.</u> 79(5):734-740 (May 1987)			
	* 68	Cockcroft et al., "Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine" <u>Am. Rev. Respir. Dis.</u> 135:264-267 (1987)			
	* 69	Cockcroft et al., "rhuMAb-E25 (E25), Humanized Murine Monoclonal Anti-IgE, Inhibits the Allergen-induced Early Asthmatic Response (EAR)" <u>J. of Allergy and Clinical Immunology</u> (Abstract no. 532) 97(1 Part III):315 (January 1996)			
	* 70	Cohn et al., "Induction of Airway Mucus Production By T Helper 2 (Th2) Cells: A Critical Role for Interleukin 4 In Cell Recruitment But Not Mucus Production" <u>Journal of Experimental Medicine</u> 186(10):1737-1747 (November 17, 1997)			
	* 71	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)			
	* 72	Conrad et al., "The Interaction of Human and Rodent IgE with the Human Basophil IgE Receptor" <u>J. of Immunology</u> 130(1):327-333 (1983)			
	* 73	Conrad, D.H., "FcεRII/CD23: The low affinity receptor for IgE" <u>Ann. Rev. Immunol.</u> 8:623-639 (1990)			
Examiner			Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	74	Corrigan & Kay, "CD4 T-Lymphocyte Activation in Acute Severe Asthma" <u>Am. Rev. Respir. Dis.</u> 141:970-977 (1990)			
	* 75	Corrigan and Kay, "T cells and eosinophils in the pathogenesis of asthma" <u>Immunology Today</u> 13:501-507 (1992)			
	* 76	Corrigan and Kay, "T-cell/eosinophil interactions in the induction of asthma" <u>Eur. Respir. J.</u> 6:72s-78s (1996)			
	77	Corrigan et al., "Role of T-lymphocytes and lymphokines" <u>Brit. Med. Bull.</u> 48(1):72-84 (1992)			
	* 78	Corrigan et al., "T Cells and Eosinophils in the Pathogenesis of Asthma" <u>Immunology Today</u> 13(12):501-507 (1992)			
	79	Corrigan et al., "T Lymphocyte Activation in Acute Severe Asthma" <u>Lancet</u> 331:1129-1131 (May 21, 1988)			
	80	Corrigan et al., "The Roles of Inflammatory Cells in the Pathogenesis of Asthma and of Chronic Obstructive Pulmonary Disease" <u>Am. Rev. Respir. Dis.</u> 143:1165-1168 (1991)			
	* 81	Coyle et al., "Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infiltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody" <u>Journal of Experimental Medicine</u> 183:1303-1310 (April 1996)			
	82	Cranston et al., "Chironomid Midges as a Cause of Allergy in the Sudan" <u>Transactions of the Royal Society of Tropical Medicine and Hygiene</u> 75(1):1-4 (1981)			
	83	Cranston et al., "Immediate-type Skin Reactivity to Extracts of the 'green nimitti' midge, (Cladotanytarsus lewisi), and other chironomids in asthmatic subjects in the Sudan and Egypt" <u>Annals of Tropical Medicine and Parasitology</u> 77(5):527-533 (1983)			
	* 84	Crescioli et al., "Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects" <u>Ann. Allergy</u> 66:245-251 (March 1991)			
	85	Cromwell et al., "Inhibition of Leukotriene C ₄ and B ₄ Generation by Human Eosinophils and Neutrophils with the Lipooxygenase Pathway Inhibitors U60257 and BW755C" <u>Int. J. Immunopharmac.</u> 7(5):775-781 (1985)			
	* 86	Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins" <u>Nucleic Acids Research</u> 19(9):2471-2476 (May 11, 1991)			
	87	Davis et al., "Can anti-IgE be used to treat allergy?" <u>Springer Seminars in Immunopathology</u> 15(1):51-73 (1993)			
	* 88	Deisenhofer, J., "Crystallographic Refinement and Atomic Models of a Human Fc Fragment and Its Complex with Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-A Resolution" <u>Biochemistry</u> 20(9):2361-2370 (1981)			
	89	Delaney et al., "Complement Components and IgE in Patients with Asthma and Aspirin Idiosyncrasy" <u>Thorax</u> 31:425-427 (1976)			
	90	Demoly et al., "Anti-IgE Therapy for Asthma" <u>American Journal of Respiratory and Crit. Care Medicine</u> 155:1825-1827 (1997)			
	91	deShazo et al., "The Late Phase Skin Reaction: Evidence for Activation of the Coagulation System in an IgE-Dependent Reaction in Man" <u>J. Immunol.</u> 122(2):692-698 (1979)			
	* 92	Diaz et al., "Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions" <u>Am. Rev. Respir. Dis.</u> 139:1383-1389 (1989)			
	* 93	Dodge et al., "The prevalence and incidence of asthma and asthma-like symptoms in a general population sample" <u>Am. Rev. Respir. Dis.</u> 122:567-575 (1980)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
94	Dolovich et al., "Late Cutaneous Allergic Responses in Isolated IgE-Dependent Reactions" <u>J. Allergy Clin. Immunol.</u> 52(1):38-45 (Jul 1973)				
95	Drazen et al., "Comparison of Regularly Scheduled with As-needed Use of Albuterol in Mild Asthma" <u>New England J. of Medicine</u> 335(12):841-847				
* 96	Duncan et al., "Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG." <u>Nature</u> 332:563-564 (April 7, 1988)				
97	Durham et al., "Eosinophils, Bronchial Hyperreactivity and Late-Phase Asthmatic Reactions" <u>Clinical Allergy</u> 15:411-418 (1985)				
98	Durham et al., "Immunologic Studies in Allergen-Induced Late-Phase Asthmatic Reactions" <u>J. Allergy Clin. Immunol.</u> 74:49-60 (1984)				
99	Durham et al., "Leukocyte Activation in Allergen-induced Late-phase Asthmatic Reactions" <u>New England J. of Medicine</u> 311(22):1398-1402 (Nov 29, 1984)				
100	Durham et al., "Platelets in Asthma" <u>Lancet</u> pps. 36 (Jul 6, 1985)				
101	Fahy et al., "'Slurry Lung': a Report of Three Cases" <u>Thorax</u> 46:394-395 (1991)				
102	Fahy et al., "Airway Inflammation and Remodeling in Asthma" <u>Curr. Opin. Pulmon. Med.</u> 6(1):15-20 (Jan 2000)				
103	Fahy et al., "Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: A method for studying allergic airway inflammation" <u>J. Allergy Clin. Immunol.</u> 93(6):1031-1039 (June 1994)				
*104	Fahy et al., "Bacteraemia and Fungaemia in Adults with Cystic Fibrosis" <u>Journal of Infection</u> 22:241-245 (1991)				
105	Fahy et al., "Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects" <u>Am. Rev. Respir. Dis.</u> 147:1126-1131 (1993)				
*106	Fahy et al., "Comparison of Samples Collected by Sputum Induction and Bronchoscopy from Asthmatic and Healthy Subjects" <u>Am. J. Respir. Crit. Care Med.</u> 152:53-58 (1995)				
107	Fahy et al., "Controversies Involving Inhaled B-Agonists and Inhaled Corticosteroids in the Treatment of Asthma" <u>Asthma</u> 16(4):715-733 (Dec 1995)				
108	Fahy et al., "Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects" <u>Am. J. Respir. Crit. Care Med.</u> 160:1023-1027 (1999)				
109	Fahy et al., "Effect of Aerosolized Pentamidine Prophylaxis on the Clinical Severity and Diagnosis of Pneumocystis Carinii Pneumonia" <u>Am. Rev. Respir. Dis.</u> 146:844-848 (1992)				
110	Fahy et al., "Effect of an NK1 Receptor Antagonist (CP-99,994) on Hypertonic Saline-Induced Bronchoconstriction and Cough in Male Asthmatic Subjects" <u>Am. J. Respir. Crit. Care Med.</u> 152:879-884 (1995)				
111	Fahy et al., "Effect of Low-dose Beclomethasone Dipropionate on Asthma Control and Airway Inflammation" <u>Eur. Respir. J.</u> 11:1240-1247 (1998)				
112	Fahy et al., "Markers of Mucus Secretion and DNA Levels in Induced Sputum from Asthmatic and from Healthy Subjects" <u>Am. Rev. Respir. Dis.</u> 147:1132-1137 (1993)				
113	Fahy et al., "Mucus Hypersecretion in Bronchiectasis" <u>Am. Rev. Respir. Dis.</u> 146:1430-1433				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	114	Fahy et al., "Reducing IgE Levels as a Strategy for the Treatment of Asthma" <u>Clin. Exp. Allergy</u> 30(Suppl. 1):16-21 (Jun 2000)			
	115	Fahy et al., "Similar RANTES Levels in Healthy and Asthmatic Airways by Immunoassay and In Situ Hybridization" <u>Am. J. Respir. Crit. Care Med.</u> 155:1095-1100 (1997)			
	*116	Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects" <u>Am J. Respir. Crit. Care Med</u> 155:1828-1834 (1997)			
	117	Fahy, J. V., "A Safe, Simple, Standardized Method Should be Used for Sputum Induction for Research Purposes" <u>Clinical and Experimental Allergy</u> 28:1047-1049 (1998)			
	118	Fahy, J. V., "Targetting IgE with Monoclonal Antibodies: the Future is Now" <u>Clinical and Experimental Allergy</u> 28:664-667 (1998)			
	119	Fahy, J.V. et al., "Respiratory pathophysiologic responses: prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation" <u>J. Allergy & Clinical Immunol.</u> 95(4):843-852 (1995)			
	*120	Fendly, B.M. et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)			
	*121	Fick et al., "Bronchoalveolar Lavage in Allergic Asthmatics" <u>Am. Rev. Respir. Dis.</u> 135:1204-1209 (1987)			
	*122	Fick et al., "Increased bronchovascular permeability after allergen exposure in sensitive asthmatics" <u>J. Appl. Physiol.</u> 63(3):1147-1155 (1987)			
	123	Fish et al., "An Evaluation of Coclicine as an Alternative to Inhaled Corticosteroids in Moderate Asthma" <u>Am. J. Respir. Crit. Care Med.</u> 156:1165-1171 (1997)			
	*124	Fisher et al., "Biostatistics: a methodology for the health sciences", New York: John Wiley & Sons pps. 861-862 (1993)			
	125	Foster et al., "Interleukin 5 Deficiency Abolishes Eosinophils, Airways, Hyperreactivity, and Lung Damage in a Mouse Asthma Model" <u>Journal of Experimental Medicine</u> 183:195-201 (Jan 1996)			
	126	Fraga et al., "Secondary Structure" <u>Computer Stimulations of Protein Structures and Interactions</u> , Berlin: Springer-Verlag, Chapter 2.3.2, pps. 16			
	127	Franz et al., "Clinical, Immunologic, and Physiologic Observations in Factory Workers Exposed to B. Subtilis Enzyme Dust" <u>J. Allergy</u> 47(3):170-180 (1971)			
	128	Frew et al., "Eosinophils and T-lymphocytes in late-phase allergic reactions" <u>The Journal of Allergy and Clinical Immunology</u> , Baltimore: C. V. Mosby Company Vol. 85(3):533-539 (Mar 1990)			
	129	Frew et al., "T Lymphocytes and Eosinophils in Allergen-Induced Late-Phase Asthmatic Reactions in the Guinea Pig" <u>Am. Rev. Respir. Dis.</u> 141:407-413 (1990)			
	130	Frew et al., "T Lymphocytes in Allergen-Induced Late-Phase Reactions and Asthma" <u>Int. Arch. Allergy Appl. Immunol.</u> 88:63-67 (1989)			
	*131	Froehlich et al., "Multiple Doses of a Recombinant Humanized Monoclonal Anti IgE Antibody Are Safely Tolerated and Decrease Free Serum IgE to Undetectable Levels" <u>J. Allergy and Clinical Immunology</u> (Abstract #863) 95(1 Part II):356 (January 1995)			
	132	Gad El Rab et al., "Widespread Immunoglobulin E-mediated Hypersensitivity in the Sudan to the "green nimitti" midge, Cladotanytarsus lewisi (diptera: Chironomidae)" <u>J. Allergy Clin. Immunol.</u> 66(3):190-197 (Sep 1980)			
	133	Gardner et al., "Standardization of Spirometry - 1987 Update" <u>American Rev. Respir. Dis.</u> 136:1285-1298 (Mar 1987)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Pick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
134	Gavett et al., "Depletion of Murine CD4+ T Lymphocytes Prevents Antigen-induced Airway Hyperreactivity and Pulmonary Eosinophilia" <u>Am. J. Respir. Cell Mol. Biol.</u> 10:587-593 (1994)				
*135	Geha et al., "IgE sites relevant for binding to type 1 Fc epsilon (FCER) receptors on mast cells" <u>J. Allergy & Clin. Immunol.</u> (Abstract No. 20) 79(1):129 (1987)				
136	Gemou-Engesaeth et al., "Activated Peripheral Blood CD4 and CD8 T-lymphocytes in Child Asthma: Correlation with Eosinophilia and Disease Severity" <u>Pediatr. Allergy Immunol.</u> 5:170-177 (1994)				
137	Gemou-Engesaeth et al., "Inhaled Glucocorticoid Therapy of Childhood Asthma Is Associated with Reduced Peripheral Blood T Cell Activation and "TH2-Type" Cytokine mRNA Expression" <u>Pediatrics</u> 99(5):695-703 (May 1997)				
138	Gershman et al., "Comparison of Two Methods of Collecting Induced Sputum in Asthmatic Subjects" <u>Eur. Respir. J.</u> 9:2448-2453 (1996)				
139	Gershman et al., "Fractional Analysis of Sequential Induced Sputum Samples During Sputum Induction: Evidence that Different Lung Compartments are Sampled at Different Time Points" <u>J. Allergy Clin. Immunol.</u> (Part 1) 104(2):322-328 (1999)				
140	Gershman et al., "Low- and high-dose Fluticasone Propionate in Asthma; Effects during and after Treatment" <u>Eur. Respir. J.</u> 15:11-18 (2000)				
141	Gershman et al., "The Effect of Methacholine Challenge on the Cellular Composition of Induced Sputum" <u>J. Allergy Clin. Immunol.</u> (Part 1) 103(5):957-959 (May 1999)				
142	Gin et al., "Airways Reversibility after Prednisolone Therapy in Chronic Asthma is Associated with Alterations in Leukocyte Function" <u>Am. Rev. Respir. Dis.</u> 132:1199-1203 (1985)				
143	Gleich, Gerald J., "The Late Phase of the Immunoglobulin E-mediated Reaction: a Link between Anaphylaxis and Common Allergic Disease" <u>Allergy Clin. Immunol.</u> 70(3):160-169 (1982)				
*144	Glennie et al., "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab'γ Fragments" <u>J. Immunol.</u> 139(7):2367-2375 (October 1, 1987)				
*145	Gonzalez et al., "Allergen-Induced Recruitment of Bronchoalveolar Helper (OKT4) and Suppressor (OKT8) T-Cells in Asthma" <u>Am. Rev. Respir. Dis.</u> 136:600-604 (1987)				
146	Gonzalo et al., "Eosinophil Recruitment to the Lung in a Murine Model of Allergic Inflammation" <u>J. Clin. Invest.</u> 98(10):2332-2345 (Nov 1996)				
*147	Gorman et al., "Reshaping a therapeutic CD4 antibody" <u>Proc. Natl. Acad. Sci. USA</u> 88(10):4181-4185 (May 15, 1991)				
*148	Grammer et al., "Diagnosis and classification of asthma" <u>Chest</u> 101(6):393S-395S (June 1992)				
149	Gr-nneberg, R., "Dual Cutaneous Reactions to Anti-human IgE; No Change in Plasma Level of the Split Product Complement C4d or Effect of Heparin" <u>Allergy</u> 40:565-570 (1985)				
*150	Gundel et al., "Endothelial Leukocyte Adhesion Molecule-1 Mediates Antigen-Induced Acute Airway Inflammation and Late-Phase Airway Obstruction in Monkeys" <u>J. Clin. Invest.</u> 88:1407-1411 (October 1991)				
*151	Haak-Frendscho et al., "Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo" <u>Immunology</u> 82:306-313 (1994)				
152	Haak-Frendscho et al., "Human IgE Receptor α chain-IgG Chimera Blocks Passive Cutaneous Anaphylaxis Reaction In Vivo" <u>J. Immunol.</u> 151(1):351-358 (1993)				
153	Haczku et al., "The Effect of Dexamethasone, cyclosporine, and rapamycin on T-lymphocyte Proliferation in Vitro: Comparison of Cells from Patients with Glucocorticoid-Sensitive and Glucocorticoid-Resistant Chronic Asthma" <u>J. Allergy Clin. Immunol.</u> 93(2):510-519 (1994)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*154	Hakimi et al., "The α subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding" <u>Journal of Biological Chemistry</u> 265(36):22079-22081 (1990)				
*155	Hammerling et al., "Production of Antibody-Producing Hybridomas in the Rodent Systems" <u>Monoclonal Antibodies and T-Cell Hybridomas</u> , New York:Elsevier, Chapter 12, pps. 563-587 (1981)				
156	Hand, John R., "Interstitial Cystitis: Report of 223 Cases (204 Women and 19 Men)." <u>J. Urol.</u> 61(2):291-310 (February 1949)				
*157	Hargreave, F.E., "Late-phase asthmatic responses and airway inflammation" <u>J. Allergy Clin. Immunol.</u> 83(2):525-527 (February 1989)				
*158	Haselden et al., "Immunoglobulin E-independent Major Histocompatibility Complex-restricted T Cell Peptide Epitope-induced Late Asthmatic Reactions" <u>Journal of Experimental Medicine</u> 189:1885-1894 (1999)				
159	Heard et al., "Mast Cells in Human Lungs" <u>Journal of Pathology</u> 157:59-63 (1989)				
*160	Helm et al., "Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ϵ -chain fragment of 76 amino acids" <u>Proc. Natl. Acad. Sci.</u> 86:9465-9469 (December 1989)				
*161	Helm et al., "The mast cell binding site on human immunoglobulin E" <u>Nature</u> 331:180-183 (January 14, 1988)				
*162	Hoffman, D. R., "Enzyme-linked immunosorbent assays (ELISA) for immunoglobulin E and blocking antibodies" <u>Methods in Enzymology</u> , Chapter 45, 73:656-666 (1981)				
163	Holgate et al., "Mast Cells, Mediators and Asthma" <u>Clinical Allergy</u> 15:221-234 (1985)				
164	Holgate et al., "Relationship between Mediator Release from Human Lung Mast Cells in vitro and in vivo" <u>Int. Archs. Allergy appl. Immun.</u> 77:47-56 (1985)				
165	Hoogenboom, Hennie R., "Overview of Antibody Phage-Display Technology and its Applications" <u>Methods in Molecular Biology</u> , P.M. O'Brien and R. Aitken, Totowa, N.J.:Humana Press Inc., Chapter 1, Vol. 178:1-37				
*166	Hook et al., "Monoclonal Antibodies Defining Epitopes on Human IgE" <u>Molecular Immunology</u> 28(6):631-639 (1991)				
*167	Hook et al., "Monoclonal antibodies defining epitopes on IgE" <u>Federation of American Societies for Experimental Biology</u> (71st Annual Meeting, Abstract #6008) pps. 1346 (1987)				
*168	Hook et al., "Monoclonal antibodies to human IgE" <u>Federation Proceedings</u> (Abstract No. 4177 Only) 40(3):968 (1994)				
169	Howarth et al., "Influence of Albuterol, Cromolyn Sodium and Ipratropium Bromide on the Airway and Circulating Mediator Responses to Allergen Bronchial Provocation in Asthma" <u>Am. Rev. Respir. Dis.</u> 132:986-992 (1985)				
170	Humbert et al., "Relationship Between IL-4 and IL-5 mRNA Expression and Disease Severity in Atopic Asthma" <u>Am. J. Resp. Crit. Care Med.</u> 156:704-708 (1997)				
171	Ihre et al., "Increase in Non-Specific Bronchial Responsiveness After Repeated Inhalation of Low Doses of Allergen" <u>Clin. Exp. Allergy</u> 23:298-305 (1993)				
172	Iikura et al., "Drug Effects on Exercise-Induced Late Asthmatic Responses" <u>NER Allergy Proc.</u> 9(3):203-207 (May 1988)				
*173	Ishizaka, K., "Immunoglobulin E (IgE)" <u>Methods in Enzymology</u> 116(Part II):76-94 (1985)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
174	Israel et al., "The Effect of Polymorphisms of the B2-Adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma" <u>Am. J. Respir. Crit. Care Med.</u> 162:75-80 (2000)				
175	Iwamoto et al., "Relationship Between Anti-IgE Autoantibody and Severity of Bronchial Asthma" <u>Int. Arch. Allergy Appl. Immunol.</u> 90:414-416 (1989)				
*176	Jaffers et al., "Monoclonal Antibody Therapy, Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression" <u>Transplantation</u> 41(5):572-578 (May 1986)				
*177	Jefferis et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγR)" <u>Molecular Immunology</u> 27(12):1237-1240 (1990)				
*178	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." <u>Nature</u> . 321:522-525 (May 29, 1986)				
*179	Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders" <u>Cancer Research</u> 50(5):1495-1502 (March 1, 1990)				
*180	Kabat <u>Sequences of Proteins of Immunological Interest</u> (Fourth Ed.), 4th edition pps. 41-42, 167-168 (1987)				
*181	Kabat <u>Sequences of Proteins of Immunological Interest</u> (pgs. 662-663, 671-672, 680-681, 697, 701-702, 710, 719-720, 2275-2276), 5th edition 1 (1991)				
182	Kanazawa et al., "Hepatitis C Virus Infection in Patients with Psoriasis" <u>Arch. Dermatol.</u> 132:1391-1392 (Nov 1996)				
183	Kay A. B., "Lymphocytes in Asthma" <u>Respiratory Medicine</u> 85(2):87-90 (1991)				
184	Kay et al., "Allergy: Conventional and Alternative Concepts: A Report of the Royal College of Physicians Committee on Clinical Immunology and Allergy" <u>Clinical and Experimental Allergy</u> (Supplement 3), Chapter 1-18, 22:vii, 1-44 (Oct 1992)				
185	Kay et al., "Complement Components and IgE in Bronchial Asthma" <u>Lancet</u> pps. 916-920 (Oct 19, 1974)				
186	Kay et al., "Corticosteroid-resistant Chronic Asthma and Monocyte Complement Receptors" <u>Clin. exp. Immunol.</u> 44:576-580 (1981)				
187	Kay et al., "Eosinophils and Neutrophils" <u>British Medical Bulletin</u> 48(1):51-64 (1992)				
188	Kay et al., "High Molecular Weight Neutrophil Chemotactic Activity in Asthma and Related Disorders" <u>Bulletin European de Physiopathologie Respiratoire</u> (and Supps. 7-9) pps. 95-99				
189	Kay et al., "Leucocyte Activation Initiated by IgE-Dependent Mechanisms in Relation to Helminthic Parasitic Disease and Clinical Models of Asthma" <u>Int. Archs. Allergy appl. Immun.</u> 77:69-72 (1985)				
190	Kay et al., "Leucocytes and the Asthma Process" <u>Allergie et Immunologie</u> 18(10):27-31 (1986)				
*191	Kay et al., "Mediators of Hypersensitivity and Inflammatory Cells in Early- and Late-Phase Asthmatic Reactions" <u>Asthma: Physiology, Immunopharmacology and Treatment (3rd Int'l Symposium)</u> (Chp. 13), Kay et al., New York:Academic Press pps. 211-227 (1984)				
192	Kay et al., "Mediators of Hypersensitivity in Exercise-Induced Asthma" <u>Eur. J. Respir. Dis.</u> (supplement 128) 64:237-241 (1983)				
193	Kay et al., "Neutrophil Chemotactic Factor of Anaphylaxis" <u>Monogr. Allergy</u> 18:284-289 (1983)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	194	Kay et al., "Non-Steroidal Anti-Inflammatory Therapy for Asthma" <u>Lancet</u> 351:672-673 (Feb 28, 1998)			
	195	Kay et al., "T-Lymphocytes, Allergy and Asthma" <u>Clin. Exp. Allergy</u> 21(Suppl. 1):17-21 (1991)			
	196	Kay et al., "The Activated Eosinophil in Allergy and Asthma" <u>Biochemistry of the Acute Allergic Reactions: Fifth International Symposium</u> , Chapter 16, pps. 183-197 (1989)			
	197	Kay et al., "The Role of Cellular Immunology in Asthma" <u>Eur. Respir. J.</u> 4(Suppl. 13):105s-112s (1990)			
	198	Kay et al., "Widespread IgE-Mediated Hypersensitivity in Northern Sudan to the Chironomid <u>Cladotanytarsus lewisi</u> ('green nimitti')" <u>Clin. exp. Immunol.</u> 34:106-110 (1978)			
	199	Kay, "Role of T Cells in Asthma" <u>Chem. Immunol.</u> (Basel, Karger) 71:178-191 (1998)			
	200	Kay, "T Cells as Orchestrators of the Asthmatic Response" <u>The Rising Trends in Asthma</u> (Ciba Foundation Symposium 206:) 206:56-70 (1997)			
	201	Kay, "T Lymphocytes and Their Products in Atopic Allergy and Asthma" <u>Int. Arch. Allergy Appl. Immunol.</u> 94:189-193 (1991)			
	*202	Kay, "TH2-Type Cytokines in Asthma" <u>Ann. N.Y. Acad. Sci.</u> 796:1-8 (1996)			
	203	Kay, A. B., "Eosinophils: Role in Asthma, Allergy and Parasite Immunity" <u>NER Allergy Proc.</u> 6(4):341-345 (1985)			
	204	Kay, A. B., "Immunosuppressive Agents in Chronic Severe Asthma" <u>Allergy Proc.</u> 15(3):147-150 (May 1994)			
	205	Kay, A. B., "Mediators and Inflammatory Cells in Allergic Disease" <u>Annals of Allergy</u> (Part II) 59:35-42 (Dec 1987)			
	206	Kay, A.B., "Basic Mechanisms in Allergic Asthma" <u>Dept. of Allergy and Clinical Immunology, Cardiothoracic Institute, Brompton Hospital, London, England</u> pps. 9-16			
	207	Kay, A.B., "Cell-mediated Immune Response in Asthma" <u>AAS</u> 28:365-373			
	208	Kay, A.B., "Eosinophils and Asthma" <u>New England J. of Medicine</u> 324(21):1514-1515 (May 23, 1991)			
	209	Kay, A.B., "Immunological Aspects of Chronic Asthma" <u>NER Allergy Proc.</u> 8(5):297-300 (Sep 1987)			
	210	Kay, A.B., "Inflammatory Cells in Bronchial Asthma" <u>Journal of Asthma</u> 26(6):335-344 (1989)			
	211	Kay, A.B., "Inflammatory Cells in Chronic Asthma" <u>Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Dovehouse Street, London</u> pps. 147-161			
	212	Kay, A.B., "Leucocytes in Asthma" <u>Immunological Investigations</u> 17(8 & 9):679-705 (1988)			
	213	Kay, A.B., "Mast Cells and their Mediators in the Pathogenesis of Asthma" <u>Eur. J. Respir. Dis.</u> (Supplement 128) 64:50-52 (1983)			
Examiner			Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
214	Kay, A.B., "Mediators of Hypersensitivity and Inflammatory Cells in the Pathogenesis of Bronchial Asthma" Dept. of Allergy and Clinical Immunology; Cardiothoracic Institute; Brompton Hospital, Fulham R; London pps. 1-44				
215	Kay, A.B., "T Cells, Cytokines and Asthma" <u>Journal of the Royal College of Physicians of London</u> 28(4):324-331 (Jul 1994)				
216	Kee et al., "High-Resolution Computed Tomography of Airway Changes After Induced Bronchoconstriction and Bronchodilation in Asthmatic Volunteers" <u>Acad. Radiol.</u> 3:389-394 (1996)				
217	Keyzer et al., "Urinary NT-methylhistamine During Early and Late Allergen-Induced Bronchial-Obstructive Reactions" <u>J. Allergy Clin. Immunol.</u> 74:240-245 (1984)				
218	Kips et al., "Methods for Sputum Induction and Analysis of Induced Sputum: a Method for Assessing Airway Inflammation in Asthma" <u>Eur. Respir. J.</u> (suppl. 26) 11:9s-12s (1998)				
*219	Kohler et al., "Derivation of Specific Antibody-producing Tissue Culture and Tumor Lines by Cell Fusion" <u>European Journal of Immunology</u> 6:511-519 (1976)				
*220	Kon and Kay, "Anti-T cell strategies in asthma" <u>Inflamm. Res.</u> 48:516-523 (1999)				
221	Kon et al., "Randomised, dose-ranging, placebo-controlled study of chimeric Antibody to CD4 (keliximab) in Chronic Severe Asthma" <u>Lancet</u> 352 (Oct 3, 1998)				
222	Kon et al., "T Cells and Chronic Asthma" <u>Int. Arch. Allergy Immunol.</u> 118:133-135 (1999)				
*223	Korsgren et al., "Allergic Eosinophil-rich Inflammation Develops in Lungs and Airways of B Cell-deficient Mice" <u>Journal of Experimental Medicine</u> 185(5):885-892 (March 1997)				
224	Krinzman et al., "Inhibition of T Cell Costimulation Abrogates Airway Hyperresponsiveness in a Murine Model" <u>J. Clin. Invest.</u> 98(12):2693-2699 (Dec 1996)				
*225	Kulczycki et al., "The Interaction of IgE with Rat Basophilic Leukemia Cells, Evidence for Specific Binding of IgE" <u>Journal of Experimental Medicine</u> 139:600-616 (1974)				
*226	Kurokawa et al., "Expression of human immunoglobulin E ϵ chain cDNA in E. coli" <u>Nucleic Acids Research</u> 11(10):3077-3085 (1983)				
*227	Larsen et al., "An Animal Model of the Late Asthmatic Response to Antigen Challenge" <u>Asthma: Physiology, Immunopharmacology and Treatment (3rd Int'l Symposium)</u> (Chp. 15), Kay et al., New York:Academic Press pps. 245-262 (1984)				
*228	Lazar et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <u>Molecular & Cellular Biology</u> 8(3):1247-1252 (Mar. 1988)				
229	Lee et al., "Allergen-Specific IgG4 in Bronchial Asthma" <u>Lancet</u> pps. 1048-1049 (Nov 6, 1982)				
230	Lee et al., "Bronchial Asthma and the Neutrophil Chemotactic Factor" <u>Clinical Allergy</u> 12:39-45 (1982)				
231	Lee et al., "Exercise-Induced Asthma and the Mast Cell" <u>Lancet</u> pps. 164-165 (Jul 16, 1983)				
232	Lee et al., "Exercise-Induced Late Asthmatic Reactions with Neutrophil Chemotactic Activity" <u>New England J. of Medicine</u> 308:1502-1505 (Jun 23, 1983)				
233	Lee et al., "Mechanism of Antigen-Induced Late Asthmatic Reactions" pps. 273-277				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
234	Lee et al., "Neutrophil Chemotactic Activity and Histamine in Atopic and Nonatopic Subjects after Exercise-induced Asthma" <u>Am. Rev. Respir. Dis.</u> 129:409-412 (1984)				
235	Lee et al., "Neutrophil Chemotactic Factor and Exercise-Induced Asthma" Dept. of Allergy and Clinical Immunology, Cardiothoracic Institute, Brompton Hospital, London, U.K. 35-42				
236	Lee et al., "Slow-Reacting Substance of Anaphylaxis Antagonist FPL 55712 in Chronic Asthma" <u>Lancet</u> 2(8241):304-305 (Feb 7, 1981)				
237	Lee et al., "The Link Between Exercise, Respiratory Heat Exchange, and the Mast Cell in Bronchial Asthma" <u>Lancet</u> pps. 520-522 (Mar 5, 1983)				
238	Lemanske et al., "Late Phase Allergic Reactions" <u>Allergy Principles and Practice</u> , Middleton, Jr. et al., Fourth edition, St. Louis, MO: Mosby-Year Books, Inc., Chapter 14, Vol. I: 320-361				
239	Liebert et al., "Evidence for Urothelial Cell Activation in Interstitial Cystitis" <u>J. Urol.</u> 149:470-475 (1993)				
240	Lim, V. I., "Algorithms for Prediction of α -Helical and β -Structural Regions in Globular Proteins" <u>J. Mol. Biol.</u> 88:873-894 (1974)				
241	Lim, V.I., "Structural Principles of the Globular Organization of Protein Chains. A Stereochemical Theory of Globular Protein Secondary Structure" <u>J. Mol. Biol.</u> 88:857-872 (1974)				
*242	Liu et al., "Expression of a biologically active fragment of human IgE ϵ chain in Escherichia coli" <u>Proc. Natl. Acad. Sci.</u> 81:5369-5373 (September 1984)				
243	Liu et al., "Neutrophil Elastase and Elastase-rich Cystic Fibrosis Sputum Degranulate Human Eosinophils in Vitro" pps. L28-L34				
244	Longphre et al., "Allergen-Induced IL-9 directly Stimulates Mucin Transcription in Respiratory Epithelial Cells" <u>The Journal of Clinical Investigation</u> 104(10):1375-1382 (Nov 1999)				
245	Lumb et al., "The Orally Administered Anti-Allergic Agent, Sodium Nivimdone (BRL 10833); Efficacy in Bronchial Asthma and Effects on IgE, Complement and Eosinophils" <u>Br. J. Clin. Pharmac.</u> 8:65-74 (1979)				
246	Mallamaci et al., "Identification of Sites on the Human FcE R1a Subunit Which are Involved in Binding Human and Rat IgE" <u>Journal of Biological Chemistry</u> 268(29):22076-22083 (Oct 15, 1993)				
*247	Marsh et al., "Increases in Airway Reactivity to Histamine and Inflammatory Cells in Bronchoalveolar Lavage after the Late Asthmatic Response in an Animal Model" <u>Am. Rev. Respir. Dis.</u> 131:875-879 (1985)				
*248	Metzger et al., "How Antibodies Work: Focus on Fc Receptors" <u>FASEB J.</u> 2(1):3-11 (January 1988)				
249	Moqbel et al., "Application of Monoclonal Antibodies Against Major Basic Protein (BMK-13) and Eosinophil Cationic Protein (EG1 and EG2) for Quantifying Eosinophils in Bronchial Biopsies from Atopic Asthma" <u>Clinical and Experimental Allergy</u> 22:265-273 (1992)				
250	Moqbel et al., "Effects of Nedocromil Sodium (Tilade) on the Activation of Human Eosinophils and Neutrophils and the Release of Histamine from Mast Cells" <u>Allergy</u> 43:268-276 (1988)				
*251	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)				
*252	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)				
*253	Murray et al., "Dust-Free Bedrooms in the Treatment of Asthmatic Children with House Dust or House Dust Mite Allergy: A Controlled Trial" <u>Pediatrics</u> 71(3):418-422 (March 1983)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	254	Nadel et al., "Asthma" <u>American Journal of Respiratory and Critical Care Medicine</u> 157(4):S130-S138 (Apr 1998)			
	255	Nagakura et al., "Neutrophil Chemotactic Factor in Exercise - and Hyperventilation-induced Asthma" <u>Am. Rev. Respir. Dis.</u> 128:294-296 (1983)			
	256	Nagy et al., "Neutrophil Chemotactic Activity in Antigen-Induced Late Asthmatic Reactions" <u>New England J. of Medicine</u> 306(9):497-501 (Mar 4, 1982)			
	*257	Nakajima et al., "CD4 ⁺ T-Lymphocytes and Interleukin-5 Mediate Antigen-induced Eosinophil Infiltration into the Mouse Trachea" <u>Am. Rev. Respir. Dis.</u> 146:374-377 (1992)			
	*258	Nakajima et al., "Effect of Saiboku-to (TJ-96) on Bronchial Asthma" <u>Annals of the New York Academy of Sciences</u> 685:549-560 (June 23, 1993)			
	*259	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function" <u>Nature</u> 314:268-270 (March 21, 1985)			
	*260	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)			
	*261	Neurath, A. R., "Use of ¹²⁵ I-labeled anti-2,4-dinitrophenyl (DNP) antibodies as a general tracer in solid-phase radioimmunoassays" <u>Methods in Enzymology</u> 73:127-138 (1981)			
	*262	Nio et al., "Inhibition of histamine release by synthetic human IgE peptide fragments: structure-activity studies" <u>Peptide Chemistry</u> pps. 203-208 (1989)			
	*263	Nissim et al., "Mapping of the high affinity Fcε receptor binding site to the third constant region domain of IgE" <u>EMBO Journal</u> 10(1):101-107 (Jan 1991)			
	*264	Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <u>Lancet</u> 335(8686):368-371 (Feb 17, 1990)			
	*265	Oi et al., "Chimeric Antibodies" <u>BioTechniques</u> 4(3):214-221 (1986)			
	266	Ordenez et al., "Increased Neutrophil Numbers and IL-8 Levels in Airway Secretions in Acute Severe Asthma" <u>American Journal of Respiratory and Critical Care Medicine</u> 161:1185-1190 (2000)			
	*267	Padlan et al., "A model of the Fc of immunoglobulin E" <u>Molecular Immunology</u> 23(10):1063-1075 (1986)			
	268	Padmanabhan et al., "Relative helix-forming tendencies of nonpolar amino acids" <u>Nature</u> 344:268-270 (Mar 15, 1990)			
	269	Papageorgiou et al., "Complement Receptor Enhancement as Evidence of Neutrophil Activation After Exercise-induced Asthma" <u>Lancet</u> pps. 1220-1223 (Nov 26, 1983)			
	270	Pienkowski et al., "Suppression of Late-Phase Skin Reactions by Immunotherapy with Ragweed Extract" <u>J. Allergy Clin. Immunol.</u> 76:729-734 (1985)			
	*271	Platts-Mills et al., "Reduction of Bronchial Hyperreactivity During Prolonged Allergen Avoidance" <u>Lancet</u> 2(8300):675-678 (September 25, 1982)			
	272	Pollart et al., "Epidemiology of Acute Asthma: IgE Antibodies to Common Inhalant Allergens as a Risk Factor for Emergency Room Visits" <u>The Journal of Allergy and Clinical Immunology</u> 83(4):875-882 (May 1989)			
	*273	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)			
Examiner			Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	274	Price et al., "A Controlled Trial of Hyposensitization with Adsorbed Tyrosine Dermatophagoides Pteronyssinus Antigen in Childhood Asthma: in Vivo Aspects" <u>Clinical Allergy</u> 14:209-219 (1984)			
	*275	Qu et al., "Expression and Characterization of a Truncated Murine Fcγ Receptor" <u>Journal of Experimental Medicine</u> 167:1195-1210 (March 1988)			
	*276	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989)			
	*277	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)			
	*278	Riske et al., "High Affinity Human IgE Receptor (FcεRI). Analysis of functional Domains of the α-Subunit with Monoclonal Antibodies" <u>Journal of Biological Chemistry</u> 266(17):11245-11251 (June 15, 1991)			
	*279	Robertson et al., "IgE structure-function relationships defined by sequence directed antibodies induced by synthetic peptides" <u>Molecular Immunology</u> 25(2):103-113 (1988)			
	280	Robertson et al., "Late Asthmatic Responses Induced by Ragweed Pollen Allergen" <u>J. Allergy Clin. Immunol.</u> 54(4):244-254 (1974)			
	281	Robinson et al., "Activated Memory T Helper Cells in Brochoalveolar Lavage Fluid from Patients with Atopic Asthma: Relation to Asthma Symptoms, Lung Function, and Bronchial Responsiveness" <u>Thorax</u> 48(1):26-32 (1993)			
	282	Robinson et al., "Activation of CD4+ T Cells, Increased TH2-type Cytokine mRNA Expression, and Eosinophil Recruitment in Bronchoalveolar Lavage after Allergen Inhalation Challenge in Patients with Atopic Asthma" <u>J. Allergy Clin. Immunol.</u> 92(2):313-324 (1993)			
	283	Robinson et al., "Evidence for Th2-Type Helper Cell Control of Allergic Disease in Vivo" <u>Springer Seminars in Immunopathology</u> 15:17-27 (1993)			
	284	Robinson et al., "Predominant TH2-Like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma" <u>New England J. of Medicine</u> 326(5):298-304 (Jan 30, 1992)			
	*285	Rup et al., "Identification of a Mouse Anti-Rat IgE Monoclonal Antibody, 44.7b, Which Inhibits IgE Binding to RBL Cells" <u>International Archives of Allergy & Applied Immunology</u> 89(4):387-393 (1989)			
	*286	Saban et al., "Human FcεRI-IgG and Humanized Anti-IgE Monoclonal Antibody MaE11 Block Passive Sensitization of Human and Rhesus Monkey Lung" <u>J. Allergy and Clinical Immunology</u> 94(5):836-843 (November 1994)			
	287	Schuster et al., "Cystic Fibrosis Sputum Induces a Secretory Response from Airway Gland Serous Cells that can be Prevented by Neutrophil Protease Inhibitors" <u>Eur. Respir. J.</u> 8:10-14 (1995)			
	*288	Schwarzbaum et al., "Mapping of murine IgE epitopes involved in IgE-Fcε receptor interactions" <u>European Journal of Immunology</u> 19:1015-1023 (1989)			
	289	Sears et al., "Relation Between Airway Responsiveness and Serum IgE in Children with Asthma and in Apparently Normal Children" <u>New England J. of Medicine</u> 325(15):1067-1071 (1991)			
	290	Shaw et al., "Activated Human Eosinophils Generate SRS-A Leukotrienes Following IgG-dependent Stimulation" <u>Nature</u> 316:150-152 (Jul 11, 1985)			
	291	Shaw et al., "Mediators of Hypersensitivity and "Fog"-induced Asthma" <u>Allergy</u> 40:48-57 (1985)			
	*292	Shaw et al., "Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses" <u>J. Nat. Canc. Inst.</u> 80(19):1553-1559 (December 7, 1988)			
	293	Shaw et al., "Nedocromil, a Mucosal and Connective Tissue Mast Cell Stabilizer, Inhibits Exercise-induced Asthma" <u>Br. J. Dis. Chest</u> 79(4):385-389			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*294	Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" <u>International Archives of Allergy and Immunology</u> 107(1-3):308-312 (May 1995)				
295	Smith et al., "An Evaluation of the Pharmacologic Inhibition of the Immediate and Late Cutaneous Reaction to Allergen" <u>J. Allergy Clin. Immunology</u> 65(2):118-121 (Feb 1980)				
296	Solley et al., "The Late Phase of the Immediate Wheal and Flare Skin Reaction" <u>J. Clin. Invest.</u> 58:408-420 (1976)				
297	Stalenheim et al., "Late Allergic Bronchial Reactions and the Effect of Allergen Provocation on the Complement System" <u>J. Allergy Clin. Immunol.</u> 75(4):508-512 (1985)				
*298	"Standardization of Spirometry - 1987 Update" <u>Am. Rev. Respir. Dis.</u> (American Thoracic Society, Medical Section of the American Lung Association) 136:1285-1298 (1987)				
*299	Stanworth et al., "Synthetic peptides comprising sequences of the human immunoglobulin E heavy chain capable of releasing histamine" <u>Biochemical Journal</u> 180(3):665-668 (1979)				
*300	Stanworth et al., "The use of synthetic peptides in the delineation of immunoglobulin antigenic epitopes and Fc effector functions" <u>Symposium on Synthetic Peptides as Antigens</u> (Ciba Foundation symposium 119), New York:Wiley Vol. 119:226-244 (1986)				
*301	Takeda et al., "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences" <u>Nature</u> 314(6010):452-454 (April 4, 1985)				
*302	Takeda et al., "Development of Eosinophilic Airway Inflammation and Airway Hyperresponsiveness in Mast Cell-deficient Mice" <u>Journal of Experimental Medicine</u> 186(3):449-454 (August 1997)				
*303	Tao and Morrison, "Studies of Aglycosylated Chimeric Mouse-Human IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region." <u>J. of Immunology</u> 143(8):2595-2601 (Oct 15, 1989)				
*304	Tepper et al., "The Role of Mast Cells and IgE in Murine Asthma" <u>Asthma Theory to Treatment</u> (Abstract Only) pps. 8 (July 15, 1995)				
305	Till et al., "Allergen-Induced Proliferation and Interleukin-5 Production by Bronchoalveolar Lavage and Blood T Cells after Segmental Allergen Challenge" <u>Am. J. Respir. Crit. Care Med.</u> 158:404-411 (1998)				
306	Till et al., "IL-5 Secretion by Allergen-Stimulated CD4+ T Cells in Primary Culture: Relationship to Expression of Allergic Disease" <u>J. Aller. Clin. Immunol.</u> 99(4):563-569 (1997)				
*307	Tung, A. S., "Production, purification, and characterization of antigen-specific murine monoclonal antibodies of IgE class" <u>Methods in Enzymology</u> , Chapter 6, 92:47-66 (1983)				
308	Turnbull et al., "Mediators of Immediate-type Hypersensitivity in Sputum from Patients with Chronic Bronchitis and Asthma" <u>Lancet</u> pps. 526-529 (Sep 10, 1977)				
309	Van de Merwe et al., "Sjogren's Syndrome in Patients with Interstitial Cystitis" <u>J. Rheumatology</u> 20:962-966 (1993)				
*310	Vercelli et al., "The B-cell binding site on human immunoglobulin E" <u>Nature</u> 338:649-651 (April 20, 1989)				
*311	Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)				
*312	Ward et al., "Theophylline--an Immunomodulatory Role In Asthma?" <u>Am. Rev. Respir. Dis.</u> 147(3):518-523 (1993)				
313	Wardlaw et al., "Bronchoalveolar Mast Cells in Extrinsic Asthma" <u>British Medical Journal</u> 291:1354 (Nov 9, 1985)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0957R1C1	Serial No. 10/826,797
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fick, Jr. et al.	
				Filing Date 16 Apr 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
314	Wardlaw et al., "Mechanisms in Asthma Using the Technique of Bronchoalveolar Lavage" <u>Int. Archs Allergy appl. Immun.</u> 82:518-525 (1987)				
315	Wardlaw et al., "Morphological and Secretory Properties of Bronchoalveolar Lavage Mast Cells in Respiratory Diseases" <u>Clinical Allergy</u> 16:163-173 (1986)				
316	Wardlaw et al., "The Role of the Eosinophil in the Pathogenesis of Asthma" <u>Allergy</u> 42:321-335 (1987)				
317	Warner et al., "Controlled Trial of Hyposensitization to Dermatophagoides Pteronyssinus in Children with Asthma" <u>Lancet</u> pps. 912-915 (Oct 28, 1978)				
318	Warner, J.O., "Significance of Late Reactions after Bronchial Challenge with House Dust Mite" <u>Arch. Dis. Child</u> 51:905-911 (1976)				
*319	Weetall et al., "Mapping the site of interaction between murine IgE and its high affinity receptor with chimeric Ig" <u>J. Immunol.</u> 145(11):3849-3854 (December 1, 1990)				
*320	Weiss et al., "The Interrelationship Among Allergy, Airways Responsiveness, and Asthma" <u>J. Asthma</u> 30(5):329-349 (1993)				
321	Wong et al., "Safety of One Method of Sputum Induction in Asthmatic Subjects" <u>Am. J. Respir. Crit. Care Med.</u> 155:299-303 (1997)				
322	Yasruel et al., "Membrane-bound and Soluble aIL-5 Receptor mRNA in the Bronchial Mucosa of Atopic and Nonatopic Asthmatics" <u>Am. J. Respir. Crit. Care Med.</u> 155:1413-1418 (1997)				
323	Ying et al., "TNF α mRNA Expression in Allergic Inflammation" <u>Clinical and Experimental Allergy</u> 21:745-750 (1991)				
324	Yssel et al., "The Role of IgE in Asthma" <u>Clinical and Experimental Allergy</u> 28(Supplement 5):104-109 (1998)				
325	Zweiman, B., "Mediators of Allergic Inflammation in the Skin" <u>Clinical Allergy</u> 18:419-433 (1988)				
*326	Zweiman, B., "The Late-Phase Reaction: Role of IgE, Its Receptor and Cytokines" <u>Current Opinion in Immunology</u> 5:950-955 (1993)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					